Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy by Sinne Søberg Brun, Torben Frøstrup Hansen, Sara Witting Christensen Wen, Christa Haugaard Nyhus, Lisbeth Bertelsen, Anders Jakobsen, Torben Schjødt Hansen, Line Nederby

Get full text